Skip to main content

WEN Acquisition Corp

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

WENN$10.470.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unaudited Condensed Balance Sheet as of June 30, 2025

UNAUDITED CONDENSED BALANCE SHEET

Assets:
Current asset
Cash$921,309
Prepaid expenses108,756
Prepaid insurance76,310
Total current asset1,106,375
Prepaid insurance – long-term70,936
Cash and marketable securities held in Trust Account301,553,603
Total Assets$302,730,914
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit:
Accrued expenses$18,673
Accrued offering expenses88,092
Due to Sponsor5,455
Total Current Liabilities112,220
Deferred underwriting fee payable14,289,750
Total Liabilities14,401,970
Commitments and Contingencies (Note 6)
Class A Ordinary Shares subject to possible redemption, 30,015,000 shares at a redemption value of $10.05 per share301,553,603
Shareholders’ Deficit
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding—
Class A Ordinary Shares, $0.0001 par value; 500,000,000 shares authorized; none issued or outstanding, excluding 30,015,000 shares subject to possible redemption—
Class B Ordinary Shares, $0.0001 par value; 50,000,000 shares authorized; 7,503,750 shares issued and outstanding750
Additional paid-in capital—
Accumulated deficit(13,225,409)
Total Shareholders’ Deficit(13,224,659)
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit$302,730,914

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

For the Three Months Ended June 30,For the Period from January 13, 2025 (Inception) Through June 30,
20252025
General and administrative costs$228,973$272,917
Loss from operations(228,973)(272,917)
Other income (expense):
Interest earned on cash and marketable securities held in Trust Account1,403,6031,403,603
Other income, net1,403,6031,403,603
Net income$1,174,630$1,130,686
Basic weighted average shares outstanding of Class A Ordinary Shares14,007,0007,503,750
Basic net income per ordinary share, Class A Ordinary Shares$0.06$0.08
Diluted weighted average shares outstanding of Class A Ordinary Shares14,007,0007,503,750
Diluted net income per ordinary share, Class A Ordinary Shares$0.05$0.08
Basic weighted average shares outstanding of Class B Ordinary Shares6,981,7506,769,688
Basic net income per ordinary share, Class B Ordinary Shares$0.06$0.08
Diluted weighted average shares outstanding of Class B Ordinary Shares7,503,7507,497,924
Diluted net income per ordinary share, Class B Ordinary Shares$0.05$0.08

UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED JUNE 30, 2025 AND

FOR THE PERIOD FROM JANUARY 13, 2025 (INCEPTION) THROUGH JUNE 30, 2025

Class A Ordinary Shares · Class B Ordinary Shares · Additional Paid-in · Accumulated · Total Shareholders’
SharesAmountSharesAmountCapitalDeficitDeficit
Balance — January 13, 2025 (inception)—$——$—$—$—$—
Class B Ordinary Shares to Sponsor——7,503,75075024,250—25,000
Net loss—————(43,944)(43,944)
Balance – March 31, 2025——7,503,75075024,250(43,944)(18,944)
Sale of 7,220,000 Private Placement Warrants————7,220,000—7,220,000
Fair value of Public Warrants at issuance————2,641,320—2,641,320
Allocated value of transaction costs to Class A Ordinary Shares————(193,726)—(193,726)
Accretion for Class A Ordinary Shares to redemption amount————(9,691,844)(14,356,095)(24,047,939)
Net income—————1,174,6301,174,630
Balance – June 30, 2025—$—7,503,750$750$—$(13,225,409)$(13,224,659)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.